Application of Megavoltage Imaging to Reduce Artifact After Seed Implants

Prostate Cancer Clinical Trial

Official title:

Application of Megavoltage Imaging to Reduce Artifact Following Interstitial Seed Implants for Prostate Adenocarcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01810627
• Other study ID #: 13-RAD-01
• Status: Completed
• Phase: N/A
• First received: March 11, 2013
• Last updated: September 22, 2017
• Start date: September 2013
• Est. completion date: April 2016

Study information

• Verified date: September 2017
• Source: University of Kentucky
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a non-randomized study to evaluate the utility of MVCT as a quality assurance measure in patients treated with interstitial permanent seed implants for low and intermediate risk prostate cancer. All patients will received the same standard of care treatment but will receive an additinoal CT image of the prostate.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: April 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 50 Years to 80 Years

Eligibility

Inclusion Criteria:

Male 50-80 years of age Eligible for interstitial brachytherapy implants

Exclusion Criteria:

Related Conditions & MeSH terms

• Prostate Cancer

Intervention

Radiation:
• MVCT
Patients will receive an additional MVCT scan at their one month follow up visit.

Locations

Country	Name	City	State
United States	Markey Cancer Center	Lexington	Kentucky

Sponsors (1)

Lead Sponsor	Collaborator
William St Clair

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in prostate volume measured in cm^3	Change in prostate volume measured with trans-rectal ultrasound at baseline versus prostate volume measured with KVCT and MVCT.	One month post implant